A rare neurological disease is Sage’s last, best hope after failures in depression

Max Gelman

Senior Editor

Ryan Cross

Senior Science Correspondent

In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery, built …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A rare neurological disease is Sage’s last, best hope after failures in depression

Max Gelman

Senior Editor

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Senior Editor

Senior Science Correspondent

Sign up to read this article for free.

A rare neurological disease is Sage’s last, best hope after failures in depression